Demand Soars For Parallel EMA-HTA Advice
This article was originally published in SRA
Executive Summary
There has been a huge increase in use by drug companies of the scheme that enables them to get simultaneous feedback on their development plans for new medicines from the European Medicines Agency and national health technology assessment (HTA) bodies.